Interferon beta-1a

"Interferon beta-1a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An interferon beta-1 subtype that has a methionine at position 1, a cysteine at position 17, and is glycosylated at position 80. It functions as an ANTI-VIRAL AGENT and IMMUNOMODULATOR and is used to manage the symptoms of RELAPSING-REMITTING MULTIPLE SCLEROSIS.

Descriptor ID	D000068556
MeSH Number(s)	D12.644.276.374.440.890.275.500 D12.776.467.374.440.890.275.500 D23.529.374.440.890.275.500
Concept/Terms	Interferon beta-1a Interferon beta-1a beta-1a, Interferon Interferon beta 1a 1a, Interferon beta beta 1a, Interferon Rebif Rebif Avonex Avonex Avonex Pen Pen, Avonex

Below are MeSH descriptors whose meaning is more general than "Interferon beta-1a".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intercellular Signaling Peptides and Proteins [D12.644.276]
Cytokines [D12.644.276.374]
Interferons [D12.644.276.374.440]
Interferon Type I [D12.644.276.374.440.890]
Interferon-beta [D12.644.276.374.440.890.275]
Interferon beta-1a [D12.644.276.374.440.890.275.500]
Proteins [D12.776]
Intercellular Signaling Peptides and Proteins [D12.776.467]
Cytokines [D12.776.467.374]
Interferons [D12.776.467.374.440]
Interferon Type I [D12.776.467.374.440.890]
Interferon-beta [D12.776.467.374.440.890.275]
Interferon beta-1a [D12.776.467.374.440.890.275.500]
Biological Factors [D23]
Intercellular Signaling Peptides and Proteins [D23.529]
Cytokines [D23.529.374]
Interferons [D23.529.374.440]
Interferon Type I [D23.529.374.440.890]
Interferon-beta [D23.529.374.440.890.275]
Interferon beta-1a [D23.529.374.440.890.275.500]

Below are MeSH descriptors whose meaning is related to "Interferon beta-1a".

Below are MeSH descriptors whose meaning is more specific than "Interferon beta-1a".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Interferon beta-1a" by people in this website by year, and whether "Interferon beta-1a" was a major or minor topic of these publications.

Bar chart showing 9 publications over 6 distinct years, with a maximum of 2 publications in 2009 and 2014 and 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	0	1	1
2009	0	2	2
2011	0	1	1
2013	0	1	1
2014	1	1	2
2015	1	1	2

Below are the most recent publications written about "Interferon beta-1a" by people in Profiles.

Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurol. 2015 Nov 11; 15:232.

View in: PubMed
Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F. Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. J Neuroimmunol. 2015 Apr 15; 281:44-50.

View in: PubMed
Tao Y, Zhang X, Chopra M, Kim MJ, Buch KR, Kong D, Jin J, Tang Y, Zhu H, Jewells V, Markovic-Plese S. The role of endogenous IFN-ß in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. J Immunol. 2014 Jun 15; 192(12):5610-7.

View in: PubMed
Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B. Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. PLoS One. 2014; 9(3):e91098.

View in: PubMed
Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013 Dec 15; 191(12):5867-74.

View in: PubMed
Ramgolam VS, Sha Y, Marcus KL, Choudhary N, Troiani L, Chopra M, Markovic-Plese S. B cells as a therapeutic target for IFN-ß in relapsing-remitting multiple sclerosis. J Immunol. 2011 Apr 01; 186(7):4518-26.

View in: PubMed
Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol. 2009 Oct 15; 183(8):5418-27.

View in: PubMed
Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol. 2009 Mar 15; 182(6):3928-36.

View in: PubMed
Lindzen E, Jewells V, Bouldin T, Speer D, Royal W, Markovic-Plese S. Progressive tumefactive inflammatory central nervous system demyelinating disease in an acquired immunodeficiency syndrome patient treated with highly active antiretroviral therapy. J Neurovirol. 2008 Nov; 14(6):569-73.

View in: PubMed

People

Markovic-Plese, Silva

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement